✦ LIBER ✦

Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)

✍ Scribed by Apostolos Tsapas; Efthymia Vlachaki; Maria Sarigianni; Filippos Klonizakis; Konstantinos Paletas

Book ID: 104040528
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 108 KB
Volume: 32
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2007.08.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term safety and efficacy of imatini

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

✍ Philippe Rousselot; Pascale Cony-Makhoul; Franck Nicolini; François Xavier Mahon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

Unexpected occurrence of second malignan

Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia

✍ Roy, L; Guilhot, J; Martineau, G; Larchée, R; Guilhot, F 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 99 KB

Safety and efficacy of STI-571 (imatinib

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)

✍ Fischer, T; Reifenrath, C; Hess, G R; Corsetti, M T; Kreil, S; Beck, J; Meinhard 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 253 KB

Reciprocal Relationship Between a Ph-Neg

Reciprocal Relationship Between a Ph-Negative Clone With Trisomy 8 Associated With Severe Myelodysplasia and a Ph-Positive Clone Following Imatinib Treatment in a Patient With Accelerated-Phase Chronic Myelogenous Leukemia (CML)

✍ Paulina Patchenko; Abraham Klepfish; Luba Trakhtenbrot; Rachel Rothman; Eliezer 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 2 views

## Cytarabine-Induced Neurotoxicity Responding to Methyl Prednisolone To the Editor: Neurotoxicity is a well-recognized complication following high-dose cytosine arabinoside (HIDAC). The pathophysiology of this toxicity is unknown, although an immune-mediated mechanism is hypothesized. We describe

Sustained remissions and low rate of BCR

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up

✍ Georg Hess; Ralf G. Meyer; Brigitte Schuch; Katja Bechthold; Ilse El-Kholy; Chri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 3 views